National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital;
Chinese Academy of Medical Sciences&Peking Union Medical College;
Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs;
Beijing 100021;
China;
Harbin Medical University Cancer Hospital;
Harbin 150081;
China;
Peking University Third Hospital;
Beijing 100191;
China;
The 307th Hospital of Military Chinese People's Liberation Army;
Beijing 100071;
China;
Tangdu Hospital of the Fourth Military Medical University;
Xi'an 710038;
China;
The Second Affiliated Hospital of Soochow University;
Suzhou 215004;
China;
The First Affiliated Hospital Zhejiang University College of Medicine;
Hangzhou 310006;
China;
Jiangsu Cancer Hospital;
Nanjing 210009;
China;
Fudan University Shanghai Cancer Center;
Shanghai 200032;
China;
The Second Affiliated Hospital Zhejiang University School of Medicine;
Hangzhou 310003;
China;
The First Affiliated Hospital of Soochow University;
Suzhou 215006;
China;
Peking University People's Hospital;
Beijing 100034;
China;
Shanghai Henlius Biotech;
Inc.;
Shanghai 200233;
China;
Biosimilar; lymphoma; monoclonal antibody; pharmacokinetics; safety;